Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Camm John) "

Sökning: WFRF:(Camm John)

  • Resultat 1-10 av 75
  • [1]234567...8Nästa
Sortera/gruppera träfflistan
  • Camm, A. John, et al. (författare)
  • Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial
  • 2012
  • Ingår i: Europace. - : Oxford University Press. - 1532-2092 .- 1099-5129. ; 14:6, s. 804-809
  • Tidskriftsartikel (refereegranskat)abstract
    • Vernakalant is a novel, relatively atrial-selective antiarrhythmic agent for conversion of atrial fibrillation (AF) to sinus rhythm. This study examined the safety and efficacy of vernakalant in converting atrial flutter (AFL) to sinus rhythm. This was a phase 2/3, randomized, double-blind, placebo-controlled trial. Adults with AFL received either a 10 min infusion of 3.0 mg/kg vernakalant (n 39) or placebo (n 15). If AFL or AF persisted at the end of a 15 min observation period, a second 10 min infusion of 2.0 mg/kg vernakalant or placebo was administered. The primary efficacy outcome was the proportion of patients who had treatment-induced conversion of AFL to sinus rhythm for a minimum duration of 1 min within 90 min after the start of the first infusion. No patient in the placebo group met the primary outcome. Only one patient receiving vernakalant (1 of 39, 3) converted to sinus rhythm. A reduced mean absolute ventricular response rate occurred within 50 min in patients receiving vernakalant (mean change from baseline 8.2 b.p.m.) vs. patients receiving placebo (0.2 b.p.m.) (P 0.037). A post-hoc analysis revealed that vernakalant increased AFL cycle length by an average of 55 ms, whereas the AFL cycle length was unchanged in the placebo group (P 0.001). There was no occurrence of 1 : 1 atrio-ventricular conduction. Dysgeusia and sneezing were the most common treatment-related adverse events, consistent with previous reports. Vernakalant did not restore sinus rhythm in patients with AFL. Vernakalant modestly slowed AFL and ventricular response rates, and was well tolerated.
  • Connolly, Stuart J, et al. (författare)
  • Dronedarone in High-Risk Permanent Atrial Fibrillation
  • 2011
  • Ingår i: New England Journal of Medicine. - 0028-4793 .- 1533-4406. ; 365:24, s. 2268-2276
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation. It also lowers heart rate and blood pressure and has antiadrenergic and potential ventricular anti-arrhythmic effects. We hypothesized that dronedarone would reduce major vascular events in high-risk permanent atrial fibrillation. Methods We assigned patients who were at least 65 years of age with at least a 6-month history of permanent atrial fibrillation and risk factors for major vascular events to receive dronedarone or placebo. The first coprimary outcome was stroke, myocardial infarction, systemic embolism, or death from cardiovascular causes. The second coprimary outcome was unplanned hospitalization for a cardiovascular cause or death. Results After the enrollment of 3236 patients, the study was stopped for safety reasons. The first coprimary outcome occurred in 43 patients receiving dronedarone and 19 receiving placebo (hazard ratio, 2.29; 95% confidence interval [CI], 1.34 to 3.94; P=0.002). There were 21 deaths from cardiovascular causes in the dronedarone group and 10 in the placebo group (hazard ratio, 2.11; 95% CI, 1.00 to 4.49; P=0.046), including death from arrhythmia in 13 patients and 4 patients, respectively (hazard ratio, 3.26; 95% CI, 1.06 to 10.00; P=0.03). Stroke occurred in 23 patients in the dronedarone group and 10 in the placebo group (hazard ratio, 2.32; 95% CI, 1.11 to 4.88; P=0.02). Hospitalization for heart failure occurred in 43 patients in the dronedarone group and 24 in the placebo group (hazard ratio, 1.81; 95% CI, 1.10 to 2.99; P=0.02). Conclusions Dronedarone increased rates of heart failure, stroke, and death from cardiovascular causes in patients with permanent atrial fibrillation who were at risk for major vascular events. Our data show that this drug should not be used in such patients.
  • Graham, Ian, et al. (författare)
  • European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).
  • 2007
  • Ingår i: European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. - : Oxford University Press (OUP). - 1741-8267. ; 14 Suppl 2, s. S1-113
  • Tidskriftsartikel (refereegranskat)abstract
    • Other experts who contributed to parts of the guidelines: Edmond Walma, Tony Fitzgerald, Marie Therese Cooney, Alexandra Dudina European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG): Alec Vahanian (Chairperson), John Camm, Raffaele De Caterina, Veronica Dean, Kenneth Dickstein, Christian Funck-Brentano, Gerasimos Filippatos, Irene Hellemans, Steen Dalby Kristensen, Keith McGregor, Udo Sechtem, Sigmund Silber, Michal Tendera, Petr Widimsky, Jose Luis Zamorano Document reviewers: Irene Hellemans (CPG Review Co-ordinator), Attila Altiner, Enzo Bonora, Paul N. Durrington, Robert Fagard, Simona Giampaoli, Harry Hemingway, Jan Hakansson, Sverre Erik Kjeldsen, Mogens Lytken Larsen, Giuseppe Mancia, Athanasios J. Manolis, Kristina Orth-Gomer, Terje Pedersen, Mike Rayner, Lars Ryden, Mario Sammut, Neil Schneiderman, Anton F. Stalenhoef, Lale Tokgözoglu, Olov Wiklund, Antonis Zampelas
  • Kirchhof, Paulus, et al. (författare)
  • Comprehensive risk reduction in patients with atrial fibrillation : emerging diagnostic and therapeutic options - a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference
  • 2012
  • Ingår i: Europace. - : Oxford University Press (OUP). - 1099-5129 .- 1532-2092. ; 14:1, s. 8-27
  • Forskningsöversikt (refereegranskat)abstract
    • While management of atrial fibrillation (AF) patients is improved by guideline-conform application of anticoagulant therapy, rate control, rhythm control, and therapy of accompanying heart disease, the morbidity and mortality associated with AF remain unacceptably high. This paper describes the proceedings of the 3rd Atrial Fibrillation NETwork (AFNET)/European Heart Rhythm Association (EHRA) consensus conference that convened over 60 scientists and representatives from industry to jointly discuss emerging therapeutic and diagnostic improvements to achieve better management of AF patients. The paper covers four chapters: (i) risk factors and risk markers for AF; (ii) pathophysiological classification of AF; (iii) relevance of monitored AF duration for AF-related outcomes; and (iv) perspectives and needs for implementing better antithrombotic therapy. Relevant published literature for each section is covered, and suggestions for the improvement of management in each area are put forward. Combined, the propositions formulate a perspective to implement comprehensive management in AF.
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 75
  • [1]234567...8Nästa
Typ av publikation
tidskriftsartikel (65)
forskningsöversikt (8)
bokkapitel (2)
Typ av innehåll
refereegranskat (73)
övrigt vetenskapligt (2)
Camm, A. John (48)
Kirchhof, Paulus (31)
Lip, Gregory Y H (26)
Blomström-Lundqvist, ... (25)
Camm, John (21)
Heidbuchel, Hein (19)
visa fler...
Hindricks, Gerhard (17)
De Caterina, Raffael ... (16)
Priori, Silvia G (16)
Goette, Andreas (15)
Tendera, Michal (14)
Zamorano, Jose Luis (14)
Dean, Veronica (14)
Sechtem, Udo (14)
Funck-Brentano, Chri ... (14)
Vahanian, Alec (14)
Ravens, Ursula (14)
Widimsky, Petr (13)
Filippatos, Gerasimo ... (13)
Boriani, Giuseppe (12)
Schotten, Ulrich (12)
Van Gelder, Isabelle ... (12)
Atar, Dan (11)
Dickstein, Kenneth (11)
Vardas, Panos (11)
Calkins, Hugh (11)
Kuck, Karl-Heinz (11)
Silber, Sigmund (11)
Bax, Jeroen (11)
McGregor, Keith (11)
Verhamme, Peter (10)
Auricchio, Angelo (10)
Sinnaeve, Peter (10)
Le Heuzey, Jean-Yves (10)
Oto, Ali (9)
Lewalter, Thorsten (9)
Crijns, Harry (9)
Willems, Stephan (9)
Oldgren, Jonas (8)
Potpara, Tatjana S (8)
Kristensen, Steen Da ... (8)
Cappato, Riccardo (8)
Steinbeck, Gerhard (8)
Hacke, Werner (7)
Alings, Marco (7)
Hohnloser, Stefan H (7)
Oldgren, Jonas, 1964 ... (7)
Mont, Lluis (7)
Brandes, Axel (7)
Savelieva, Irene (7)
visa färre...
Uppsala universitet (51)
Lunds universitet (13)
Göteborgs universitet (8)
Karolinska Institutet (8)
Umeå universitet (3)
Linköpings universitet (2)
visa fler...
Kungliga Tekniska Högskolan (1)
Örebro universitet (1)
visa färre...
Engelska (69)
Italienska (3)
Polska (2)
Portugisiska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (46)


Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy